Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1947 • ACR Convergence 2022
Medication Use in Childhood Sjogren Disease
Erin Treemarcki¹, Matthew Basiaga², Scott Lieberman³ and Sara Stern¹, ¹University of Utah, Salt Lake City, UT, ²Mayo Clinic, Inver Grove Heights, MN, ³University of Iowa, Iowa City, IA
Background/Purpose: Childhood Sjogren’s Disease (childSD) is a rare complex chronic autoimmune disease primarily affecting lacrimal and salivary glands. Currently there is a paucity of information…
Abstract Number: 2032 • ACR Convergence 2022
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
Kunal Chandwar¹, Juhi Dixit¹, Kriti Kishor¹, DOGGA PRASANNA KUMAR², DIGVIJAY EKBOTE³, PUNEET KUMAR¹ and Urmila Dhakad¹, ¹King George's Medical University, Lucknow, India, ²KGMU, LUCKNOW, Uttar Pradesh, India, ³KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India
Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
Abstract Number: 2048 • ACR Convergence 2022
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
Gaetano La Rocca¹, Francesco Ferro², Giovanni Fulvio³, Silvia Fonzetti⁴, Inmaculada Concepción Navarro García⁵, Elena Elefante⁶, Chiara Romei⁷, Marta Mosca⁶ and Chiara Baldini³, ¹University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Pisa, Italy, ⁴Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶University of Pisa, Pisa, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a relatively frequent manifestation of Sjögren's Syndrome (pSS), potentially presenting with a wide spectrum of clinical-radiological characteristics. Anti-Ro52 autoantibodies…
Abstract Number: 0005 • ACR Convergence 2021
Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome
Mathijs Broeren¹, Giulia Balzaretti², Jing Wang³, Patricia Groenen¹, Barbera van Schaik⁴, Tim Chataway³, Charlotte Kaffa¹, Sander Bervoets¹, Konnie Hebeda¹, Gergana Bounova⁵, Ger Pruijn¹, Tom Gordon³, Niek De Vries⁶ and Rogier Thurlings⁷, ¹Radboud University Medical Center, Nijmegen, Netherlands, ²Amsterdam, Netherlands, ³Flinders University, Adelaide, Australia, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Enpicom BV, Den Bosch, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Sjögren's syndrome (SjS) involves chronic inflammation of exocrine glands that can be complicated by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). We…
Abstract Number: 0310 • ACR Convergence 2021
Histopathology, Salivary Flow and Ultrasonography of the Parotid Gland: Three Complementary Measurements in Primary Sjögren’s Syndrome
Martha S. van Ginkel¹, Esther Mossel², Erlin A. Haacke², Suzanne Arends³, Silvia Liefers¹, Konstantina Delli¹, Jolien F. van Nimwegen⁴, Alja J. Stel⁵, Fred Spijkervet¹, Arjan Vissink⁶, Bert van der vegt¹, Frans Kroese³ and Hendrika Bootsma³, ¹University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Center Groningen, Groningen, ³University Medical Center Groningen, Groningen, Netherlands, ⁴Univeristy of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁶University of Groningen, University Medical Center Groningen, Leek, Netherlands
Background/Purpose: Primary Sjögren’s syndrome is a systemic autoimmune disease characterized by dryness of the mouth and eyes. The impact of the disease on salivary glands…
Abstract Number: 0839 • ACR Convergence 2021
Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
Lisa Christ¹, Seraphina Kissling², Ruediger B. Mueller³, Axel Finckh⁴, Benjamin Fisher⁵, Britta Maurer¹, Burkhard Moeller⁶ and Florian Kollert¹, ¹Department of Rheumatology and Immunology, University Hospital (Inselspital) and University of Bern, Bern, Switzerland, ²Statistics and Data Management Group, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, ³Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ⁴University Hospital of Geneva, Geneve - Vesenaz, Switzerland, ⁵Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: The variety of treatment options in RA contrasts with a lack of personalized medicine. The presence of concomitant SjS might be associated with differerences…
Abstract Number: 0165 • ACR Convergence 2021
Shear-Wave Elastography Evaluation of Major Salivary Glands and Correlation with B-mode Findings in Patients with Primary Sjögren’s Syndrome
Ana Prata¹, Joao Freitas², Mary Lucy Marques³, Flavio Costa⁴, Mariana Santiago⁵, Sara Serra¹, Margarida Coutinho¹, Tânia Santiago¹, João Pedro Lopes Rovisco¹ and Jose Pereira da Silva⁶, ¹Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ²Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Centro Hospitalar de Vila Nova de Gaia/Espinho, Coimbra, Portugal, ⁵Centro Hospitalar e Universitário de Coimbra, Unknown, Colombia, ⁶University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal
Background/Purpose: Salivary-gland ultrasound has recently shown to help in the diagnosis and monitoring of primary Sjögren’s syndrome (pSS)1. Shear-wave elastography (SWE) is a promising tool…
Abstract Number: 0311 • ACR Convergence 2021
Ultra High‐frequency Ultrasound (UHFUS) of Labial Glands in Primary Sjögren’s Syndrome: Serological and Histological Correlations
Giovanni Fulvio¹, Francesco Ferro¹, Rossana Izzetti², Gianmaria Governato¹, Silvia Fonzetti¹, Gaetano La Rocca¹, Valentina Donati³, Davide Caramella⁴, Marta Mosca⁵ and Chiara Baldini⁶, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²University of Pisa, Unit of Dentistry and Oral Surgery, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, Pisa, Italy, ³AOUP, Unit of Pathological Anatomy, Pisa, Italy, ⁴University of Pisa, 3Diagnostic and Interventional Radiology, Department of Translational Research and of New Technologies in Medicine and Surgery, Pisa, Italy, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁶University of Pisa, Pisa, Italy
Background/Purpose: Last‐generation ultra high‐frequency ultrasound (UHFUS) transducers are highly sensitive tools potentially able to open new avenues for the identification of imaging biomarkers. Recently UHFUS…
Abstract Number: 0984 • ACR Convergence 2021
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Kevin Sheng-Kai Ma, Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philidelphia, PA
Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…
Abstract Number: 0296 • ACR Convergence 2021
The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US
Briana Ndife¹, Sophie Barlow², Megan Hughes² and Nicola Booth², ¹Novartis, East Hanover, NJ, ²Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Diagnosis of primary Sjögren’s syndrome (pSS) is challenging due to the disease’s phenotypic heterogeneity. pSS patients frequently experience a prolonged period between symptomatic onset…
Abstract Number: 0312 • ACR Convergence 2021
Prognostic Value of Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome
Francesco Ferro¹, Gianmaria Governato¹, Giovanni Fulvio¹, Gaetano La Rocca¹, Silvia Fonzetti¹, Giacomo Aringhieri², Valentina Donati³, Marta Mosca⁴ and Chiara Baldini⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²University of Pisa, 3Diagnostic and Interventional Radiology, Department of Translational Research and of New Technologies in Medicine and Surgery, Pisa, Italy, ³AOUP, Unit of Pathological Anatomy, Pisa, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁵University of Pisa, Pisa, Italy
Background/Purpose: In the last decade, salivary gland ultrasonography (SGUS) has appeared as a useful tool for the diagnosis of primary Sjögren’s syndrome (pSS) and for…
Abstract Number: 0985 • ACR Convergence 2021
Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers
Sara McCoy¹, Miguel Woodham¹, Ian Saldanha², Esen Akpek³, VATINEE BUNYA⁴ and Alan Baer⁵, ¹University of Wisconsin, Madison, WI, ²Brown University School of Public Health, Providence, RI, ³Wilmer Eye Institute, JHU, Baltimore, MD, ⁴University of Pennsylvania, Penn Valley, PA, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjӧgren’s syndrome (SS) patients have lower quality of life driven by symptoms of pain, depression and fatigue. These symptoms often do not respond to…
Abstract Number: 0297 • ACR Convergence 2021
Describing the Disease Burden of Primary Sjögren’s Syndrome Patients: Results from a Real-World Survey in the US
Briana Ndife¹, Ben Hoskin², Megan Hughes² and Nicola Booth², ¹Novartis, East Hanover, NJ, ²Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Primary Sjogren’s syndrome is a highly heterogeneous condition, with limited understanding of the burden of disease. The objective of this study was to describe…
Abstract Number: 0313 • ACR Convergence 2021
Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease?
Katja Perdan Pirkmajer¹, Matija TOMSIC¹ and Alojzija Hocevar², ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²UKC Ljubjana, Ljubjana, Slovenia
Background/Purpose: Ultrasonographically depicted morphological changes of major salivary glands (SG) have been recently correlated with the disease activity in primary Sjögren’s (pSS)1. The aim of…
Abstract Number: 0986 • ACR Convergence 2021
Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
Thomas Dörner¹, Simon J Bowman², Robert Fox³, Xavier Mariette⁴, Athena Papas⁵, Thomas Grader-Beck⁶, Ben A Fisher², Filipe Barcelos⁷, Salvatore De Vita⁸, Hendrik Schulze-Koops⁹, Robert Moots¹⁰, Guido Junge¹¹, Janice Woznicki¹², Monika Sopala¹¹, Wen-Lin Luo¹² and Wolfgang Hueber¹¹, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Scripps Memorial Hospital and Research Institute, San Diego, CA, ⁴Université Paris- Saclay, Rheumatology, Paris, France, ⁵Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁶Johns Hopkins University, Baltimore, MD, ⁷Instituto Português de Reumatologia, Lisbon, Portugal, ⁸Division of Rheumatology, DAME, University Hospital of Udine, Udine, Italy, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹⁰Academic Rheumatology Department, Aintree University Hospital, Liverpool, United Kingdom, ¹¹Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease affecting excretory glands and characterized by B-cell hyperactivity. Ianalumab (VAY736) is a human monoclonal antibody to B-cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.